Roland Griffiths

School of Medicine Johns Hopkins University, Baltimore, MD 
Behavioral Pharmacology
"Roland Griffiths"
Mean distance: 15.22 (cluster 23)


Sign in to add trainee
John D.Roache grad student Johns Hopkins Medical School (PsychTree)
Lawrence P. Carter post-doc Johns Hopkins
Thomas S. Critchfield post-doc Johns Hopkins (PsychTree)
Matthew Johnson post-doc Johns Hopkins (PsychTree)
R J. Lamb post-doc Johns Hopkins
Katherine A. MacLean post-doc Johns Hopkins
Chad J. Reissig post-doc Johns Hopkins
Mary M Sweeney post-doc Johns Hopkins Medical School (PsychTree)
Frederick Streeter Barrett post-doc 2013- Johns Hopkins Medical School
Manoj K. Doss post-doc 2018- Johns Hopkins Medical School
Jack E. Henningfield post-doc 1978-1980 Johns Hopkins
Scott E. Lukas post-doc 1979-1982 Johns Hopkins
Stephen T. Higgins post-doc 1983-1985 Johns Hopkins
Warren K. Bickel post-doc 1984-1985 Johns Hopkins
Martin Iguchi post-doc 1986-1988 Johns Hopkins
Kenneth Silverman post-doc 1989-1991 Johns Hopkins
Elise Weerts post-doc 1993-1995
Thomas Eissenberg post-doc 1994-1996
Miriam Z. Mintzer post-doc 1995-1998 Johns Hopkins
Laura M. Juliano post-doc 2001-2002 American University (PsychTree)
Laura M. Juliano post-doc 2001-2002 American University (PsychTree)
Stacey C. Sigmon post-doc 2002-2004 Johns Hopkins (PsychTree)
Steven  E. Meredith post-doc 2012-2014 Johns Hopkins
Albert P. Garcia-Romeu post-doc 2012-2016 Johns Hopkins (PsychTree)
Albert P. Garcia-Romeu post-doc 2012-2016 Johns Hopkins (PsychTree)
Theresa Carbonaro post-doc 2013-2016
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Carbonaro TM, Johnson MW, Griffiths RR. (2020) Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology
Davis AK, Clifton JM, Weaver EG, et al. (2020) Survey of entity encounter experiences occasioned by inhaled -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology (Oxford, England). 269881120916143
Sweeney MM, Weaver DC, Vincent KB, et al. (2020) Prevalence and Correlates of Caffeine Use Disorder Symptoms Among a United States Sample. Journal of Caffeine and Adenosine Research. 10: 4-11
Barrett FS, Doss MK, Sepeda ND, et al. (2020) Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports. 10: 2214
Garcia-Romeu A, Cox DJ, Smith KE, et al. (2020) Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence. 107849
Garcia-Romeu A, Davis AK, Erowid E, et al. (2019) Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry. 10: 955
Garcia-Romeu A, Davis AK, Erowid F, et al. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology (Oxford, England). 269881119845793
Griffiths RR, Hurwitz ES, Davis AK, et al. (2019) Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. Plos One. 14: e0214377
Davis AK, So S, Lancelotta R, et al. (2019) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse. 1-9
Sweeney MM, Meredith SE, Juliano LM, et al. (2018) A randomized controlled trial of a manual-only treatment for reduction and cessation of problematic caffeine use. Drug and Alcohol Dependence. 195: 45-51
See more...